FDA Releases Draft Guidance on Evaluating Late Radiation Toxicity of Therapeutic Radiopharmaceuticals

Summary

The FDA has made available a draft guidance document aimed at helping the pharmaceutical industry design nonclinical studies to assess the potential late radiation toxicities of therapeutic radiopharmaceuticals, with the goal of reducing the risk of irreversible radiation injuries in clinical trials.